Propofol Market Size, Share, Growth, and Industry Analysis, By Type (Powder,Liquid), By Application (Sedation,Anesthesia), Regional Insights and Forecast to 2035

Propofol Market Overview

The global Propofol Market size is projected to grow from USD 1036.67 million in 2026 to USD 1075.65 million in 2027, reaching USD 1444.86 million by 2035, expanding at a CAGR of 3.76% during the forecast period.

The global Propofol Market is a critical segment of the anesthetic drugs sector, with the total market size recently estimated at approximately USD 1,400 million in 2024. The Propofol Market accounts for a significant share of general anesthesia drug consumption, dominating nearly 25%–26% of that segment. In the Propofol Market, intravenous formulations constitute about 65% of usage volume.

In the United States, propofol is a dominant intravenous anesthetic, with the leading player holding up to 71% share of U.S. usage in recent years. The U.S. general anesthesia drugs market was valued at USD 1.72 billion in 2024, within which propofol represents its largest share (≈ 25–30%).

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 65 % of anesthetic procedures globally use propofol as induction agent
• Major Market Restraint: 40 % of hospitals maintain strict generic substitution rules limiting premium formulations
• Emerging Trends: 35 % of new propofol formulations emphasize improved lipid emulsion stability
• Regional Leadership: North America contributes ~40 % share of propofol consumption
• Competitive Landscape: One manufacturer accounts for ~50 % of global propofol production capacity
• Market Segmentation: Liquid dosage form comprises ~65 % share by usage volume
• Recent Development: A key manufacturer expanded production capacity by 20 % between 2023 and 2025

Propofol Market Latest Trends

In the Propofol Market Trends, formulation innovation is prominent: approximately 35 % of new propofol launches between 2023–2025 focus on enhanced lipid emulsion stability or lower excipient load to reduce adverse reactions. Another trend is prefilled syringe adoption, which has grown ~28 % globally in the past two years, driven by workflow efficiency in operating rooms. The shift toward ambulatory surgeries also fuels demand, as ~20 % of propofol doses now serve outpatient settings rather than inpatient ORs.

Propofol Market Dynamics

The Propofol Market Dynamics are shaped by a complex balance of rising surgical volumes, regulatory pressures, innovation in formulations, and shifting regional demand. With more than 26 million surgeries performed annually in the U.S. and propofol used in approximately 65% of anesthetic inductions worldwide, the market is underpinned by a consistent baseline of demand.

DRIVER

"Rising surgical volumes and minimally invasive procedures"

The primary driver in the Propofol Market is the increasing number of surgical and procedural interventions that require safe and rapid induction agents. For instance, in the U.S. alone over 26 million surgeries were performed in 2022. Globally, the number of operating rooms and outpatient surgical centers has expanded by ~4–6 % annually in recent years, driving propofol consumption.

RESTRAINT

"Regulatory burden, liability risks, and generic competition"

A key restraint in the Propofol Market is the high regulatory and liability risk associated with anesthetic agents. For example, Teva previously held ~40 % of U.S. market share and faced a $356 million liability settlement related to contamination issues.

OPPORTUNITY

"Emerging markets and new formulation niches"

The Propofol Market holds significant opportunity in underserved emerging regions such as Africa, Latin America, and parts of Asia. In India and Southeast Asia, surgical capacity expansion is adding ~1,000 new OR rooms annually. Local manufacturers can leverage import substitution policies to capture ~15–25 % cost advantages.

CHALLENGE

"Safety incidents, supply chain disruptions, and raw material volatility"

One major challenge in the Propofol Market is managing safety and contamination risk: ~5 lot recalls in 2023–2024 due to sterility or stability issues have shaken confidence. Supply chain disruptions, especially for lipid excipients and specialized containers (e.g. glass vials compliant with inert coatings), have caused ~10 % production delays.

Propofol Market Segmentation

Segmentation in the Propofol Market is by Type (Powder, Liquid) and by Application (Sedation, Anesthesia). Liquid propofol dominates, representing about 65 % of usage by volume, while powder (reconstituted) forms the remainder. On the application side, general anesthesia consumes about 70–75 % of propofol usage, with sedation (ICU, procedural) making up 25–30 %.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Powder: The powder form of propofol is marketed in lyophilized vials requiring reconstitution prior to use. Although less immediately convenient, powder offerings account for ~35 % of overall volume in certain regions with cold-chain or stability constraints. Powder propofol is favored in markets where transport logistics are challenging or storage is space constrained.

The Propofol Powder segment is valued at USD 349.7 million in 2025, holding 35.0% share of the total market, and is projected to reach USD 486.3 million by 2034 at a CAGR of 3.76%, supported by cost-efficient logistics, long-shelf-life stability, and strong adoption in regions with limited cold chain capacity.

Top 5 Major Dominant Countries in the Powder Segment

• United States: The U.S. Propofol Powder Market is valued at USD 105.2 million in 2025, representing 30.1% share of the segment, and projected to grow to USD 146.3 million by 2034 with a CAGR of 3.8%, driven by consistent hospital demand for long-shelf-life anesthetic formulations in critical care and outpatient surgical settings.
• Germany: The Germany Propofol Powder Market is valued at USD 48.7 million in 2025, accounting for 13.9% global share, and is forecast to increase to USD 67.7 million by 2034 with a CAGR of 3.7%, supported by strict pharmaceutical regulations and widespread adoption of sterile powdered anesthetics across advanced surgical facilities.
• China: The China Propofol Powder Market is estimated at USD 46.2 million in 2025, representing 13.2% of global share, and is projected to reach USD 64.2 million by 2034 at a CAGR of 3.8%, driven by rapidly expanding surgical procedure volumes and large-scale growth of generic propofol production capacity.
• Japan: The Japan Propofol Powder Market is valued at USD 40.9 million in 2025, holding 11.7% market share, and is forecast to grow to USD 56.8 million by 2034 with a CAGR of 3.7%, supported by steady procurement cycles, standardized hospital anesthesia protocols, and strong reliance on powder formulations in surgical operations.
• India: The India Propofol Powder Market is valued at USD 32.5 million in 2025, accounting for 9.3% of global share, and is projected to expand to USD 45.1 million by 2034 with a CAGR of 3.8%, reflecting increased operating room capacity, government-backed healthcare investments, and expanding hospital adoption of powder-based anesthetic supplies.

Liquid: Liquid propofol (emulsion ready for injection) is the dominant type, capturing ~65 % of usage globally. The convenience of immediate use, absence of reconstitution steps, and reduced risk of preparation error drive hospital preference.

The Propofol Liquid segment is valued at USD 649.4 million in 2025, representing 65.0% of the overall market, and is forecast to reach USD 906.2 million by 2034 at a CAGR of 3.76%, supported by strong hospital preference, convenience of immediate administration, and rising adoption of prefilled syringes across advanced healthcare facilities worldwide.

Top 5 Major Dominant Countries in the Liquid Segment

• United States: The U.S. Propofol Liquid Market is valued at USD 194.1 million in 2025, holding 29.9% share of the global segment, and is expected to reach USD 270.9 million by 2034 with a CAGR of 3.8%, driven by strong demand in surgical suites and rapid adoption of prefilled syringe formats.
• Germany: The Germany Propofol Liquid Market is valued at USD 84.3 million in 2025, accounting for 13.0% of global share, and is projected to expand to USD 117.7 million by 2034 with a CAGR of 3.7%, supported by advanced ICU sedation needs and strict adherence to hospital procurement standards.
• China: The China Propofol Liquid Market is estimated at USD 82.9 million in 2025, representing 12.8% of global share, and is expected to grow to USD 115.5 million by 2034 with a CAGR of 3.8%, fueled by rising surgical volumes in tier-one hospitals and rapid modernization of healthcare systems.
• Japan: The Japan Propofol Liquid Market is valued at USD 74.3 million in 2025, holding 11.4% market share, and is projected to reach USD 103.5 million by 2034 with a CAGR of 3.7%, supported by ongoing modernization of anesthetic delivery systems and stable demand from both pediatric and adult anesthesia use.
• India: The India Propofol Liquid Market is valued at USD 61.0 million in 2025, representing 9.4% of global share, and is forecast to grow to USD 85.0 million by 2034 with a CAGR of 3.8%, driven by expanding ambulatory surgical centers, increasing hospital procurement, and rising adoption of liquid formulations in high-volume operating rooms.

BY APPLICATION

Sedation: The sedation application consists of ICU sedation, procedural sedation (endoscopy, imaging), and sedated diagnostic procedures. Sedation accounts for ~25–30 % of total propofol usage by volume. In some ICU units, up to ~30 % of ventilated patients receive continuous propofol infusions for sedation management.

The Propofol Sedation segment is valued at USD 299.7 million in 2025, accounting for 30.0% share of the total market, and is projected to reach USD 417.8 million by 2034 with a CAGR of 3.76%, driven by rising ICU ventilator cases, diagnostic endoscopy procedures, and growing reliance on propofol for sedation in critical and outpatient care settings.

Top 5 Major Dominant Countries in the Sedation Application

• United States: The U.S. Propofol Sedation Market is valued at USD 104.9 million in 2025, representing 35.0% share of the global segment, and is expected to reach USD 146.3 million by 2034, supported by widespread use in ICU ventilated patients and diagnostic procedures such as colonoscopy and imaging sedation.
• Germany: The Germany Propofol Sedation Market is estimated at USD 42.9 million in 2025, holding 14.3% of the segment’s share, and forecasted to rise to USD 59.8 million by 2034, driven by strict hospital guidelines favoring propofol sedation in intensive care and surgical recovery units.
• China: The China Propofol Sedation Market is valued at USD 41.5 million in 2025, representing 13.8% of global share, and is projected to increase to USD 57.9 million by 2034, fueled by rising hospital expansions, higher ICU admissions, and rapid adoption in endoscopy centers nationwide.
• Japan: The Japan Propofol Sedation Market is valued at USD 38.1 million in 2025, accounting for 12.7% of global share, and expected to grow to USD 53.2 million by 2034, supported by high diagnostic procedure volumes and stable hospital procurement cycles for sedatives in outpatient surgery centers.
• India: The India Propofol Sedation Market is projected at USD 28.7 million in 2025, holding 9.6% market share, and is forecasted to reach USD 40.1 million by 2034, reflecting growth in mid-tier hospital sedation procedures and increased diagnostic imaging volumes requiring anesthetic support.

Anesthesia: The anesthesia application encompasses induction and maintenance in surgical, obstetric, and neurological procedures. Anesthesia accounts for roughly 70–75 % of global propofol consumption. In global OR settings, propofol is the preferred induction agent in over 65 % of surgeries. It is used in both adult and pediatric anesthesia, with pediatric dosing making up ~12–15 % of the anesthesia volume.

The Propofol Anesthesia segment is valued at USD 699.4 million in 2025, representing 70.0% of the total market, and is expected to expand to USD 974.7 million by 2034 with a CAGR of 3.76%, primarily supported by rising global surgical procedures, high operating room demand, and established preference for propofol as the induction agent of choice across diverse surgical specialties.

Top 5 Major Dominant Countries in the Anesthesia Application

• United States: The U.S. Propofol Anesthesia Market is valued at USD 273.1 million in 2025, representing 39.0% share of the global segment, and is projected to grow to USD 380.5 million by 2034, driven by more than 26 million annual surgical procedures utilizing propofol as the primary anesthetic induction agent.
• Germany: The Germany Propofol Anesthesia Market is valued at USD 90.1 million in 2025, accounting for 12.9% of the segment’s share, and expected to reach USD 125.5 million by 2034, supported by dense hospital surgical networks and stringent anesthesia protocols requiring propofol across multiple medical disciplines.
• China: The China Propofol Anesthesia Market is estimated at USD 87.6 million in 2025, representing 12.5% of global share, and is projected to grow to USD 121.7 million by 2034, driven by large-scale increases in surgical volume and government-backed hospital expansions across urban and semi-urban regions.
• Japan: The Japan Propofol Anesthesia Market is valued at USD 77.1 million in 2025, accounting for 11.0% of the segment’s share, and forecasted to reach USD 107.0 million by 2034, supported by both adult and pediatric anesthesia procedures, alongside continued modernization of operating room facilities.
• India: The India Propofol Anesthesia Market is projected at USD 59.9 million in 2025, representing 8.6% of global share, and is expected to expand to USD 83.0 million by 2034, fueled by rising operating room capacity, growing middle-class access to surgical care, and government healthcare infrastructure programs.

Regional Outlook for the Propofol Market

The Propofol Market shows strong concentration in North America (≈ 40 % share), followed by Europe (≈ 20–25 %), Asia-Pacific (≈ 25 %), and Middle East & Africa (≈ 7 –10 %). The fastest growth is occurring in Asia-Pacific and select emerging markets as surgical capacity expands. North America leads in adoption of branded and high-purity formulations, while Europe contributes significant production capacity. In the Middle East & Africa, propofol demand is rising but constrained by infrastructure.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands approximately 40 % share of the global Propofol Market, making it the largest regional market by usage and influence. The U.S. general anesthesia drugs market was valued at USD 1.72 billion in 2024, within which propofol is the dominant intravenous agent, representing ~25–30 % of overall volume. In the U.S., one manufacturer reportedly held up to 71 % share of propofol shipments in recent years, exhibiting extreme concentration of supply.

The North America Propofol Market is valued at USD 399.6 million in 2025, representing 40.0% share of the global market, and is projected to reach USD 556.6 million by 2034 with a CAGR of 3.76%, driven by high surgical volumes exceeding 26 million annually, strong adoption of ICU sedation practices, and growing demand for prefilled syringes in hospital operating rooms and ambulatory surgical centers.

North America – Major Dominant Countries in the Propofol Market

• United States: The U.S. Propofol Market is valued at USD 299.7 million in 2025, holding 75.0% share of the regional market, and is forecast to increase to USD 417.8 million by 2034, driven by widespread use in anesthesia induction, ICU sedation, and procedural diagnostics across advanced healthcare systems.
• Canada: The Canada Propofol Market is valued at USD 39.9 million in 2025, representing 10.0% of regional share, and is expected to reach USD 55.7 million by 2034, supported by healthcare reforms, hospital expansions, and increased integration of propofol into anesthesia and sedation protocols.
• Mexico: The Mexico Propofol Market is estimated at USD 29.9 million in 2025, accounting for 7.5% share of the regional segment, and projected to grow to USD 41.8 million by 2034, driven by new private hospital investments and expansion of surgical facilities in urban centers.
• Cuba: The Cuba Propofol Market is valued at USD 14.0 million in 2025, representing 3.5% share of the region, and is forecast to expand to USD 19.5 million by 2034, primarily supported by state-backed procurement of generic propofol and hospital-focused anesthetic programs.
• Dominican Republic: The Dominican Republic Propofol Market is projected at USD 16.1 million in 2025, accounting for 4.0% regional share, and expected to increase to USD 22.5 million by 2034, driven by expansion of surgical facilities, government healthcare programs, and rising demand for propofol in outpatient centers.

EUROPE

Europe holds an estimated 20–25 % share of global propofol usage, with several Western European nations dominating procurement and production. For example, in Europe, the propofol market size in 2024 was reported at USD 405.66 million, representing ~30 % share of global drug revenues. Key countries like Germany, U.K., France, Italy, and Spain are major users and producers of propofol. In Germany, propofol consumption is high due to dense surgical infrastructure, and German firms contribute significantly to global manufacturing.

The Europe Propofol Market is valued at USD 249.8 million in 2025, representing 25.0% share of the global market, and is projected to reach USD 347.3 million by 2034 with a CAGR of 3.76%, supported by advanced pharmaceutical production hubs, widespread surgical activity, and strong adoption of premium propofol formulations across Germany, U.K., France, Italy, and Spain.

Europe – Major Dominant Countries in the Propofol Market

• Germany: The Germany Propofol Market is valued at USD 74.9 million in 2025, representing 30.0% share of the regional market, and forecasted to grow to USD 104.2 million by 2034, supported by dense hospital surgical networks and strong reliance on high-quality liquid formulations.
• United Kingdom: The U.K. Propofol Market is valued at USD 54.9 million in 2025, holding 22.0% regional share, and projected to reach USD 76.5 million by 2034, driven by National Health Service investments and strong use in both inpatient and outpatient procedures.
• France: The France Propofol Market is estimated at USD 49.9 million in 2025, representing 20.0% of the regional share, and forecasted to expand to USD 69.3 million by 2034, supported by steady procedural growth and consistent hospital demand for anesthetics.
• Italy: The Italy Propofol Market is projected at USD 39.9 million in 2025, representing 16.0% share of the regional segment, and expected to rise to USD 55.7 million by 2034, supported by modernization of hospital facilities and increased access to surgical care.
• Spain: The Spain Propofol Market is valued at USD 31.2 million in 2025, holding 12.5% of the regional share, and forecasted to grow to USD 44.6 million by 2034, fueled by high surgical volumes and growing reliance on propofol-based anesthesia protocols.

ASIA-PACIFIC

The Asia-Pacific region contributes approximately 25 % share to global propofol usage and is among the fastest expanding markets, as surgical access and healthcare infrastructure grow rapidly. In 2024, China’s propofol market share was estimated at USD 139.95 million, India’s at USD 37.32 million, Japan at USD 42.92 million, and South Korea at USD 31.10 million, signaling high regional diversity. The rise in middle-class healthcare demand, government hospital expansions, and growing outpatient procedure adoption push volume growth.

The Asia Propofol Market is valued at USD 249.8 million in 2025, representing 25.0% share of the global market, and is projected to reach USD 347.3 million by 2034 at a CAGR of 3.76%, driven by rapid hospital infrastructure growth, rising surgical volumes in China, India, and Southeast Asia, and strong expansion of generic propofol production across the region.

Asia – Major Dominant Countries in the Propofol Market

• China: The China Propofol Market is valued at USD 87.5 million in 2025, accounting for 35.0% regional share, and forecasted to reach USD 121.7 million by 2034, driven by significant increases in surgeries and expanding generic manufacturing capabilities.
• Japan: The Japan Propofol Market is estimated at USD 62.4 million in 2025, holding 25.0% of the regional share, and projected to grow to USD 86.8 million by 2034, supported by advanced hospital networks and adoption of modern anesthesia practices.
• India: The India Propofol Market is valued at USD 49.9 million in 2025, representing 20.0% regional share, and is projected to expand to USD 69.3 million by 2034, supported by government healthcare expansion and new hospital construction.
• South Korea: The South Korea Propofol Market is estimated at USD 31.2 million in 2025, holding 12.5% of regional share, and is forecast to reach USD 43.4 million by 2034, fueled by high demand in surgical centers and outpatient facilities.
• Australia: The Australia Propofol Market is projected at USD 18.7 million in 2025, representing 7.5% share of the regional segment, and expected to grow to USD 26.1 million by 2034, supported by consistent hospital demand and widespread procedural adoption.

MIDDLE EAST & AFRICA

Middle East & Africa (MEA) currently holds around 7–10 % share of the Propofol Market, with gradual growth tied to healthcare expansion and tertiary hospital development. The region includes key markets such as Saudi Arabia, UAE, South Africa, Egypt, and Nigeria, where propofol demand is rising in government and private sector hospitals. In UAE and Saudi Arabia, hospital networks often procure premium formulations and prefilled syringes — ~20–25 % of propofol orders in these countries use prefilled formats.

The Middle East & Africa Propofol Market is valued at USD 99.9 million in 2025, representing 10.0% share of the global market, and projected to reach USD 139.3 million by 2034 with a CAGR of 3.76%, driven by GCC healthcare investments, increasing hospital capacity, and growing adoption of propofol for anesthesia and sedation across both public and private healthcare systems.

Middle East & Africa – Major Dominant Countries in the Propofol Market

• Saudi Arabia: The Saudi Arabia Propofol Market is valued at USD 25.0 million in 2025, accounting for 25.0% of the regional share, and projected to grow to USD 34.8 million by 2034, supported by Vision 2030 hospital expansions and strong anesthetic procurement programs.
• United Arab Emirates: The UAE Propofol Market is estimated at USD 20.0 million in 2025, representing 20.0% of regional share, and forecasted to rise to USD 27.8 million by 2034, driven by private hospital developments and adoption of advanced anesthetic protocols.
• South Africa: The South Africa Propofol Market is valued at USD 18.0 million in 2025, holding 18.0% share of the region, and expected to reach USD 25.0 million by 2034, supported by hospital modernization programs and strong reliance on generic propofol supplies.
• Egypt: The Egypt Propofol Market is projected at USD 16.0 million in 2025, accounting for 16.0% of the regional share, and forecasted to increase to USD 22.3 million by 2034, driven by growing surgical volumes and healthcare infrastructure expansion.
• Nigeria: The Nigeria Propofol Market is valued at USD 12.0 million in 2025, representing 12.0% of the regional segment, and is expected to grow to USD 16.7 million by 2034, fueled by rising demand for surgical procedures and increasing ICU capacity in urban hospitals.

List of Top Propofol Companies

• Pfizer, Inc.
• Aspen
• Teva Pharmaceutical Industries Ltd.
• SI Group
• Bachem
• Nhwa
• Xian Libang
• Braun Melsungen AG
• SGPharma Pvt. Ltd.
• Baxter International, Inc.
• Fresenius Kabi AG

Bachem: Bachem controls nearly 50% of global propofol manufacturing capacity, specializing in high-purity formulations and supplying across over 70 countries with advanced production infrastructure.

Fresenius Kabi AG: Fresenius Kabi dominates with approximately 71% U.S. market share, providing liquid and prefilled propofol formulations, supported by strong hospital networks and large-scale global production facilities.

Investment Analysis and Opportunities

From an investment viewpoint, the Propofol Market presents solid opportunities given the stable base demand from surgical and sedation uses. Institutional and strategic investors have allocated increasing capital into anesthetic formulation and CMO expansions. Between 2023 and 2025, one major player expanded capacity by ~20 %, while another regional manufacturer added ~50 % output to serve Asia demand. Emerging markets represent investment hotspots: Africa and Latin America currently command <10 % of consumption but house ~30–40 % of global population — expanding infrastructure could unlock multi-fold growth.

New Product Development

Innovation in the Propofol Market centers on formulation, delivery and packaging. Currently ~35 % of new product development efforts focus on high-stability lipid emulsions that resist phase separation under temperature stress. Prefilled syringe formats are proliferating: in 2023–2025, more than a dozen new prefilled propofol systems launched globally. Some innovations include low-lipid concentration variants aimed at reducing hemodynamic suppression, representing ~10 new formulations in early trials. Others integrate smart syringe compatibility, e.g. propofol cartridges optimized for closed-system infusion pumps.

Five Recent Developments

• A leading manufacturer expanded propofol production capacity by 20 % in 2024 to meet rising demand in Asia-Pacific.
• In 2025, Bachem reaffirmed its position as global leader with ~50 % of manufacturing capacity, securing long-term feedstock contracts.
• A U.S. supplier achieved ~71 % domestic market share for propofol formulations in the U.S. region in recent years.
• In 2024, ~5 lots of propofol vials were recalled globally due to stability or sterility deviations, prompting stricter QA protocols.
• A contract manufacturer in India increased output by ~50 % between 2023 and 2025, enabling regional supply to Southeast Asia.

Report Coverage of Propofol Market

The Propofol Market Report Coverage includes a comprehensive framework of global and regional analyses, covering over 100 countries, with segmentation by type (powder, liquid), application (sedation, anesthesia), and regional splits (North America, Europe, Asia-Pacific, Middle East & Africa). The report typically comprises ~150–200 pages, featuring more than 120 tables and charts, and includes detailed Propofol Market Insights, Propofol Market Share breakdowns, and forward projections across 5–10 years. For each region, the report delves into supply-demand balances, local manufacturing capacity, import/export flows, regulatory environment, and pricing dynamics.

Propofol Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1036.67 Million in 2026
Market Size Value By	USD 1444.86 Million by 2035
Growth Rate	CAGR of 3.76% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Powder Liquid By Application : Sedation Anesthesia
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample